
    
      This study is an open label, prospective, multicenter, non-randomized single-arm study to
      evaluate the safety and efficacy of the closing iatrogenic atrial septal defects in patients
      undergoing transcatheter mitral valve procedures using large sheaths.

      A maximum of 5 Clinical Sites (referred to as "Sites" in the remainder of this document) in
      the U.S. Two hundred and ten patients will be enrolled in this study. The patients will
      randomized 1:2 device: control. The anticipated accrual rate is approximately 20 Subjects per
      month for a total accrual period of approximately 12-18 months.

      Patients may be enrolled into the study provided all inclusion and no exclusion criteria are
      met as specified in Section 4. Subjects will be evaluated through hospital discharge and
      return for follow-up visits at 30 days, 6 months, and 12 months.
    
  